130 related articles for article (PubMed ID: 38437799)
1. Characterization of Transthyretin Mutation G47V Associated with Hereditary Cardiac Amyloidosis.
He X; Wang M; Sun J; Yu Z; Hu X; Liu Y; Lin X
Cardiology; 2024 Mar; ():. PubMed ID: 38437799
[TBL] [Abstract][Full Text] [Related]
2. Clinical and biochemical characterization of hereditary transthyretin amyloidosis caused by E61K mutation.
Chu X; Wang M; Tang R; Huang Y; Yu J; Cao Y; Zheng Y; Xie Z; Deng J; Wang Z; Ma W; Song W; Wu Y; Lv H; Zhang W; Wang Z; Yuan Y; Liu Y; Meng L
Front Mol Neurosci; 2022; 15():1003303. PubMed ID: 36311011
[No Abstract] [Full Text] [Related]
3. Biochemical and biophysical properties of a rare TTRA81V mutation causing mild transthyretin amyloid cardiomyopathy.
Sha Q; Zhang Y; Wang M; Sun J; Zhang Y; Zhang X; Wang N; Liu Y; Liu Y
ESC Heart Fail; 2024 Feb; 11(1):112-125. PubMed ID: 37827496
[TBL] [Abstract][Full Text] [Related]
4. Biochemical and biophysical properties of an unreported T96R mutation causing transthyretin cardiac amyloidosis.
Jiang M; Wang M; Tao Z; Chai Y; Liu Q; Lu Q; Wu Q; Ying X; Huang Y; Nie Y; Tang Y; Zhang X; Liu Y; Pu J
Amyloid; 2023 Jun; 30(2):188-198. PubMed ID: 36350689
[TBL] [Abstract][Full Text] [Related]
5. Identification of a novel transthyretin mutation D39Y in a cardiac amyloidosis patient and its biochemical characterizations.
Ma Q; Wang M; Huang Y; Nie Y; Zhang X; Yang DD; Wang Z; Ding S; Qian N; Liu Y; Pan X
Front Cardiovasc Med; 2023; 10():1091183. PubMed ID: 36776255
[TBL] [Abstract][Full Text] [Related]
6. Transthyretin: Its function and amyloid formation.
Ueda M
Neurochem Int; 2022 May; 155():105313. PubMed ID: 35218869
[TBL] [Abstract][Full Text] [Related]
7. An ultra performance liquid chromatography method for transthyretin variants screening and heart failure assisting diagnosis.
Wang S; Guan L; Sun Y; Cui L; Guo S; Wang M; Liu Y; Cui X; Zhao F; Zhang Y; Cao Y
Clin Chim Acta; 2024 Jan; 553():117709. PubMed ID: 38103852
[TBL] [Abstract][Full Text] [Related]
8. Characterization of heterozygous ATTR Tyr114Cys amyloidosis-specific induced pluripotent stem cells.
Ouchi K; Isono K; Ohya Y; Shiraki N; Tasaki M; Inomata Y; Ueda M; Era T; Kume S; Ando Y; Jono H
Heliyon; 2024 Jan; 10(2):e24590. PubMed ID: 38312695
[TBL] [Abstract][Full Text] [Related]
9. Transthyretin Stabilization by AG10 in Symptomatic Transthyretin Amyloid Cardiomyopathy.
Judge DP; Heitner SB; Falk RH; Maurer MS; Shah SJ; Witteles RM; Grogan M; Selby VN; Jacoby D; Hanna M; Nativi-Nicolau J; Patel J; Rao S; Sinha U; Turtle CW; Fox JC
J Am Coll Cardiol; 2019 Jul; 74(3):285-295. PubMed ID: 30885685
[TBL] [Abstract][Full Text] [Related]
10. Glavonoid, a possible supplement for prevention of ATTR amyloidosis.
Matsushita H; Isoguchi A; Okada M; Masuda T; Misumi Y; Tsutsui C; Yamaguchi N; Ichiki Y; Sawashita J; Ueda M; Mizuguchi M; Ando Y
Heliyon; 2021 Oct; 7(10):e08101. PubMed ID: 34693047
[TBL] [Abstract][Full Text] [Related]
11. Prognosis of Transthyretin Cardiac Amyloidosis Without Heart Failure Symptoms.
Gonzalez-Lopez E; Escobar-Lopez L; Obici L; Saturi G; Bezard M; Saith SE; AbouEzzeddine OF; Mussinelli R; Gagliardi C; Kharoubi M; Griffin JM; Dispenzieri A; Vilches S; Perlini S; Longhi S; Oghina S; Rivas A; Grogan M; Maurer MS; Damy T; Palladini G; Rapezzi C; Garcia-Pavia P
JACC CardioOncol; 2022 Nov; 4(4):442-454. PubMed ID: 36444226
[TBL] [Abstract][Full Text] [Related]
12. Diagnosis of genetic amyloidosis through the analysis of transthyretin gene mutation using high-resolution melting.
Lahuerta C; Menao S; Gracia-Gutierrez A; Bueno-Juana E; Guillén N; Sorribas V; Gracia AA; Aibar MA
Int J Cardiol; 2020 Feb; 301():220-225. PubMed ID: 31740141
[TBL] [Abstract][Full Text] [Related]
13. Prevalence, characteristics and outcomes of older patients with hereditary versus wild-type transthyretin amyloid cardiomyopathy.
Porcari A; Razvi Y; Masi A; Patel R; Ioannou A; Rauf MU; Hutt DF; Rowczenio D; Gilbertson J; Martinez-Naharro A; Venneri L; Whelan C; Lachmann H; Wechalekar A; Quarta CC; Merlo M; Sinagra G; Hawkins PN; Fontana M; Gillmore JD
Eur J Heart Fail; 2023 Apr; 25(4):515-524. PubMed ID: 36644836
[TBL] [Abstract][Full Text] [Related]
14. Conventional Molecular Dynamics and Metadynamics Simulation Studies of the Binding and Unbinding Mechanism of TTR Stabilizers AG10 and Tafamidis.
Zhou S; Ge S; Zhang W; Zhang Q; Yuan S; Lo GV; Dou Y
ACS Chem Neurosci; 2020 Oct; 11(19):3025-3035. PubMed ID: 32915538
[TBL] [Abstract][Full Text] [Related]
15. Characteristics of Patients with Hereditary Transthyretin Amyloidosis-Polyneuropathy (ATTRv-PN) in NEURO-TTRansform, an Open-label Phase 3 Study of Eplontersen.
Coelho T; Waddington Cruz M; Chao CC; Parman Y; Wixner J; Weiler M; Barroso FA; Dasgupta NR; Jung SW; Schneider E; Viney NJ; Dyck PJB; Ando Y; Gillmore JD; Khella S; Gertz MA; Obici L; Berk JL
Neurol Ther; 2023 Feb; 12(1):267-287. PubMed ID: 36525140
[TBL] [Abstract][Full Text] [Related]
16. Late onset cardiomyopathy as presenting sign of ATTR A45G amyloidosis caused by a novel TTR mutation (p.A65G).
Klaassen SHC; Lemmink HH; Bijzet J; Glaudemans AWJM; Bos R; Plattel W; van den Berg MP; Slart RHJA; Nienhuis HLA; van Veldhuisen DJ; Hazenberg BPC
Cardiovasc Pathol; 2017; 29():19-22. PubMed ID: 28460244
[TBL] [Abstract][Full Text] [Related]
17. Asp58Ala is the predominant mutation of the TTR gene in Korean patients with hereditary transthyretin-related amyloidosis.
Jang MA; Lee GY; Kim K; Kim SJ; Kim JS; Lee SY; Kim HJ; Jeon ES
Ann Hum Genet; 2015 Mar; 79(2):99-107. PubMed ID: 25644864
[TBL] [Abstract][Full Text] [Related]
18. First Norwegian case of hereditary ATTR amyloidosis with a novel transthyretin variant.
Lyng CS; Gude E; Hodt A; Knudsen EC
Scand Cardiovasc J; 2023 Dec; 57(1):2174269. PubMed ID: 36734834
[TBL] [Abstract][Full Text] [Related]
19. AG10 inhibits amyloidogenesis and cellular toxicity of the familial amyloid cardiomyopathy-associated V122I transthyretin.
Penchala SC; Connelly S; Wang Y; Park MS; Zhao L; Baranczak A; Rappley I; Vogel H; Liedtke M; Witteles RM; Powers ET; Reixach N; Chan WK; Wilson IA; Kelly JW; Graef IA; Alhamadsheh MM
Proc Natl Acad Sci U S A; 2013 Jun; 110(24):9992-7. PubMed ID: 23716704
[TBL] [Abstract][Full Text] [Related]
20. Advances in the treatment of transthyretin cardiac amyloidosis: Current and emerging therapies.
Warner AL
Pharmacotherapy; 2021 Dec; 41(12):1081-1091. PubMed ID: 34669976
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
